Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.
April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.
Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.
Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?
What do on-demand PrEP advances seen in men mean for a developing a biomedical prevention agenda for women?